Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-311996


The COVID19 pandemic has been transmitted worldwide rapidly. The best ways of preventing this virus are to know about and act accordingly. An online cross sectional survey was conducted to know the knowledge, attitude and practices towards COVID19 and to assess the risks of infections among Bangladeshi population. Among 2045 respondents, 54·87% respondents kept good knowledge. Knowledge was significantly diverged across age, gender, education levels, residences, income groups, and marital status. Despite the knowledge, the attitude and practices of Bangladeshi people are not impressive. Among population, 32·08%, and 44·30% people were in high, and in medium risk of infection respectively. Everybody is in risk. Reasons for the mediocre attitude and practices could be the poor knowledge, nonscientific and orthodox religious believe. Government and policy makers must consider these knowledge levels, attitude & practices and the risk of infection assessment to implement productive interventions for preventing the COVID19.

J Neuroimmunol ; 356: 577590, 2021 07 15.
Article in English | MEDLINE | ID: covidwho-1217589


A 50-years old male presented with quadriplegia and paresthesia and was diagnosed as Guillain-Barré syndrome (GBS). He was found positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) six weeks prior to the onset of weakness. GBS disability score was 4. Electrophysiology showed acute inflammatory demyelinating polyradiculopathy. Anti-SARS-CoV-2 IgG was found positive. Immunological tests for Campylobacter jejuni, Zika virus, Hepatitis E virus, Herpes Simplex virus, Haemophilus influanzae and Mycoplasma pneumoniae were negative. Patient received standard dose of intravenous immunoglobulin and after six months had almost complete recovery of muscle power. This case represents possible association of SARS-CoV-2 infection and GBS with good clinical outcome.

COVID-19/complications , Guillain-Barre Syndrome/virology , Follow-Up Studies , Guillain-Barre Syndrome/drug therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Male , Middle Aged , SARS-CoV-2 , Time